 keytruda franchis remain linchpin
messag earn call refer truda pipelin within
drug three major trial lung cancer read year includ
discuss greater detail possibl merck
set larg cancer meet schedul june chicago
opportun possibl reveal data total emerg far away
leader lung cancer report earn ahead
consensu guidanc estim earn
oncolog keytruda lynparza epacadostat
manag plan present data soon possibl appropri
medic meet believ could year readout
monotherapi patient chemotherapi combin squamou
nsclc close one could expect may present three trial one packag
emerg medic meet potenti command substanti
lead set lung pend posit trial data one could imagin late-
breaker present assum surviv benefit achiev well public
major medic journal mrk dr roger perlmutt remain confid strength
data believ result could similar trial
design way accord manag keytruda alreadi market leader
across io non-io therapi nsclc keytruda grew yoy
 ex-u respect manag provid follow contributor keytruda
sale cancer indic lung melanoma head neck bladder
rest
believ lung cancer share could substanti increas public detail
enabl market accordingli remind data
ad label immedi trial design ident
manag refer difficulti obtain reliabl data break sale
indic ex-u major contributor remain melanoma new indic
gain traction furthermor manag highlight realli expans
monotherapi cite also patient low express
respons keytruda accord manag opportun benefici
safeti profil compar monotherapi benefici toxic profil
compar chemotherapi combin dr perlmutt said individu
younger combin therapi might attract older patient
mani comorbid combin therapi might less attract irrespect
express overal manag remain optimist keytruda see
foundat therapi oncolog would agre see commentari around keytruda
along line expect
accord manag lynparza regain class leadership follow approv
broader ovarian cancer label astrazeneca azn current
launch new metastat breast cancer indic manag see signific long-
term opportun lynparza manag provid much commentari around
keytruda plu epacadostat highlight benefici safeti profil
combin manag said question much benefit one get
efficaci point view along line expec
vaccin gardasil zostavax
sale reflect increment sale approxim due record
vaccin sale european countri part sanofi sni vaccin joint
ventur termin dec sale gardasil came
qoq addit sale includ partial replenish
page analyst certif import disclosur
dose gardasil borrow cdc vaccin stockpil
effect borrow subsequ partial replenish result net reduct
sale million howev accord manag underli growth
increas coverag rate remain strong ex-u gardasil saw growth
europ sanofi sni joint ventur termin well increas demand
asia pacif gardasil launch china believ factor could contribut
futur growth despit qoq declin manag believ
male femal receiv least first dose underlin notion
growth opportun even ex-u believ signific opportun
hand zostavax sale declin significantli qoq primarili due
cdc advisori committe recommend glaxo gsk shingrix prefer
vaccin see press releas manag expect continu pressur zostavax sale
 believ could also pressur futur follow approv
eu note chmp recent adopt posit opinion shingrix see
ww sale januvia franchis nearli volum trend remain
strong market per compani face continu price pressur particularli
 maintain market-lead access anticip growth opportun
intern market increas import januvia franchins beyond
januvia tri expand diabet launch steglatro steglujan
believ steglatro ertugliflozin approv late adult may enter
market earli monotherapi well combin januvia steglujan
metformin segluromet believ steglujan could possibl mitig loe
januvia mention share howev may depend
cardiovascular outcom studi hypothes posit consid
cv benefit may class effect note steglatro monotherapi enter
crowd market azn play field alreadi
made adjust model base result guidanc
manag commentari compani earn call rais
revenu estim base guidanc strong perform sever key
product quarter keytruda sale estim increas futur year
expect posit data readout follow addit approv line extens
keytruda updat sg estim due opex guidanc
provid compani well gross margin estim result manag
comment expect slight decreas vs addit updat
expect tax rate beyond result effect recent tax
legisl model tax rate slight declin subsequ year
expect abl lower non-gaap effect tax rate time
valuat risk
valuat valuat methodolog base dcf analysi believ
best captur overal valu busi merck dcf take
present valu cash flow within forecast window thereaft wind exist
product busi includ risk-adjust contribut pipelin asset use
lt growth rate wacc translat dcf valu price target
current trade ep estim
estim revenu approxim
risk risk rate valuat includ setback key pipelin asset high
competit market competitor bristol-my roch
rhhbi similar compound ident therapeut area hcv competit
increas spend clinic trial particularli line extens keytruda
page analyst certif import disclosur
million except per-shar figur
equiti loss incom affili
net incom attribut non-controlling interest
page analyst certif import disclosur
